Non Small Cell Lung Cancer
Showing NaN - NaN of 45
Solid Tumor, Adult, Colorectal Cancer, NSCLC Trial in United States (A2B694, xT CDx with HLA-LOH Assay)
Not yet recruiting
- Solid Tumor, Adult
- +19 more
- A2B694
- xT CDx with HLA-LOH Assay
-
Duarte, California
- +9 more
Sep 22, 2023
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer Trial in United States (A2B530, xT-Onco with HLA-LOH Assay)
Not yet recruiting
- Solid Tumor, Adult
- +15 more
- A2B530
- xT-Onco with HLA-LOH Assay
-
Duarte, California
- +6 more
Feb 10, 2023
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)
Recruiting
- Triple Negative Breast Cancer
- +14 more
- LYL797
-
Scottsdale, Arizona
- +10 more
Jan 30, 2023
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer Trial in United States (device, drug, radiation, procedure)
Active, not recruiting
- Non Small Cell Lung Cancer
- Stage III Non-small-cell Lung Cancer
- Durvalumab
- +4 more
-
Chicago, Illinois
- +3 more
Jan 18, 2023
Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer Trial in Israel, United States (CM-24 and Nivolumab - Dose
Recruiting
- Solid Tumor
- +6 more
- CM-24 and Nivolumab - Dose Escalation
- +4 more
-
Scottsdale, Arizona
- +10 more
Jan 17, 2023
Non Small Cell Lung Cancer, KRAS Activating Mutation Trial in Worldwide (VS-6766, VS-6766 and Defactinib)
Recruiting
- Non Small Cell Lung Cancer
- KRAS Activating Mutation
- avutometinib (VS-6766)
- avutometinib (VS-6766) and Defactinib
-
Duarte, California
- +44 more
Dec 22, 2022
Non Small Cell Lung Cancer Trial in United States (N-803 + Pembrolizumab, N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab,
Active, not recruiting
- Non Small Cell Lung Cancer
- N-803 + Pembrolizumab
- +5 more
-
Anchorage, Alaska
- +30 more
Nov 3, 2022
Tumors, Metastatic Cancer, Advanced Cancer Trial in United States (Niraparib, TSR-042, Carboplatin-Paclitaxel)
Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer Trial in San Francisco, Denver, San Antonio (P-MUC1C-ALLO1 CAR-T
Recruiting
- Breast Cancer
- +8 more
- P-MUC1C-ALLO1 CAR-T cells
- Rimiducid
-
San Francisco, California
- +4 more
Oct 26, 2022
Non Small Cell Lung Cancer Trial in Tampa, Houston (quaratusugene ozeplasmid, pembrolizumab, docetaxel)
Recruiting
- Non Small Cell Lung Cancer
- quaratusugene ozeplasmid
- +3 more
-
Tampa, Florida
- +2 more
Sep 12, 2022
Mesothelioma, Glioblastoma, Renal Cell Carcinoma Trial in Korea, Republic of, Taiwan, United States (NGM707, NGM707 plus
Recruiting
- Mesothelioma
- +14 more
- NGM707
- NGM707 plus pembrolizumab
-
Los Angeles, California
- +13 more
Aug 16, 2022
Advanced Solid Tumor, Metastatic Cancer, Refractory Cancer Trial in Huntersville, Houston, Webster (PT199, Anti-PD-1 mAb)
Recruiting
- Advanced Solid Tumor
- +18 more
- PT199
- Anti-PD-1 monoclonal antibody
-
Huntersville, North Carolina
- +2 more
Aug 10, 2022
Pancreatic Cancer, Breast Cancer, Gastric Cancer Trial in Grand Rapids, New York, Houston (NGM438, Pembrolizumab)
Recruiting
- Pancreatic Cancer
- +15 more
-
Grand Rapids, Michigan
- +2 more
Jul 18, 2022
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer Trial in United States (NT-I7,
Recruiting
- Any Advanced Solid Tumors
- +6 more
-
Tampa, Florida
- +7 more
Jul 13, 2022
Oncology, Solid Tumor, Non Small Cell Lung Cancer Trial in United States (MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution
Active, not recruiting
- Oncology
- +5 more
- MRx0518
- Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
-
Kansas City, Kansas
- +4 more
Jul 5, 2022
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer Trial in Worldwide (INCB106385, INCMGA00012)
Recruiting
- Ovarian Cancer
- +10 more
-
West Hollywood, California
- +27 more
Jun 27, 2022
Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer Trial in Worldwide (Combination of NKTR-214 + nivolumab)
Completed
- Melanoma
- +6 more
- Combination of NKTR-214 + nivolumab
-
La Jolla, California
- +57 more
Jun 22, 2022